Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Toyota Global Sales Fall as China Demand Slumps 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Add as a preferred source on Google
SAN JOSE, Calif., April 04, 2018 -- According to the latest market report published by Credence Research, Inc. “Parkinson’s Disease Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2018 - 2026” the global Parkinson’s disease therapeutics market, was valued at US$ 2.41 Bn in 2017, and is expected to reach US$ 3.95 Bn by 2026 expanding at a CAGR of 5.6% from 2018 to 2026.
Market Insights:
Parkinson's disease is a type of progressive movement disorder, characterized by muscle rigidity, and tremors. The global Parkinson's disease therapeutics market will grow significantly over the forecast period, majorly due to presence of late stage pipeline drugs such as APL-130277, Accordion Pill, P2B-001, ND0612H etc. and rising incidence of the disease. For the purpose of the study, the global Parkinson's disease therapeutics market is categorized on the basis of drug class such as dopamine agonists, levodopa/carbidopa, anticholinergic drugs, monoamine oxidase B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors and adenosine A2 receptor antagonist. Levodopa coupled with carbidopa remains the standard treatment of Parkinson disease which shows fewer adverse effects in short-term use. Dopamine agonists are widely accepted for treatment of PD used as alone or in combination with levodopa/carbidopa.
At present, North America leads the global PD therapeutics market owning to larger patient pool, advantage of early diagnosis, developed healthcare infrastructure and increase in prevalence of PD. It is predicted that PD therapeutics market in Asia Pacific will demonstrate lucrative growth over the forecast period because of rising prevalence of PD and improving healthcare infrastructure with developing economic condition.
Market Competition Assessment:
It is observed that, companies such as Abbvie, Inc., Biogen, Inc., Boehringer Ingelheim GmbH, F. Hoffman-La Roche, GlaxoSmithKline Plc., H. Lundbeck A/S, Impax Labs, Inc., Newron Pharmaceuticals SpA, Novartis AG, Orion Corporation, Teva Pharmaceutical Industries Ltd., UCB S.A. etc. are key players involved in R&D and manufacturing of PD therapeutics market.
Browse Full Report With TOC, Figures And Tables @ http://www.credenceresearch.com/report/parkinsons-disease-therapeutics-market
About Us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.
Contact:
Name: Chris Smith
Designation: Global Sales Manager
E-mail: [email protected]
Ph: +1-800-361-8290
Connect With US:
Web: Credence Research
Facebook @ https://www.facebook.com/CredenceResearch
Twitter @ https://twitter.com/CredenceResearc
LinkedIn @ https://us.linkedin.com/company/credenceresearch
G+ @ https://plus.google.com/+Credenceresearch
